(PR-inside.com) Signature Diagnostics / Signature Diagnostics to Present a novel Companion Diagnostic Product Predicting Response to Cetuximab in Colorectal Cancer at the 102nd AACR Meeting in Orlando . Processed and transmitted by Thomson Reuters ONE. The issuer is solely responsible for the content of this announcement. Potsdam, Germany, April 6, 2011 - Signature Diagnostics AG announced today that the company was selected to present its novel companion diagnostics for predicting response to Cetuximab in patients with colorectal cancer (CRC) of all stages at the 102nd Annual Meeting of the ..
More...
More...